RESEARCH CHEMICAL ONLY — FOR IN VITRO / LABORATORY USE
This information is provided exclusively for educational and scientific reference purposes. This compound is NOT approved by the FDA or any regulatory agency for human or veterinary use. Administration into living organisms is FORBIDDEN BY LAW in many jurisdictions without appropriate licensure. All data presented here is sourced from peer-reviewed literature and is intended solely for in vitro (outside-the-body) research contexts.
This website does not provide medical advice, diagnosis, or treatment. Consult a licensed physician before making any health-related decisions.
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a 39–amino-acid synthetic peptide acylated with a C20 fatty di-acid that binds albumin for a once-weekly half-life. It is the first approved medication to activate both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, and is marketed by Eli Lilly as Mounjaro (type 2 diabetes) and Zepbound (obesity and obstructive sleep apnea), with development code LY3298176.
Combining GIP and GLP-1 agonism produces additive effects on insulin secretion, appetite, and energy balance beyond what single-incretin agents like Semaglutide achieve. Like semaglutide, tirzepatide is an FDA-approved drug validated in large randomized trials — so, as with that page, the evidence below reflects human clinical data, not the preclinical work typical of research peptides.
Research Context
Evidence Level: Tirzepatide is an FDA-approved drug supported by large, multi-year randomized controlled trials (RCTs) in humans. The findings below summarize published trial results. This page is educational and does not replace medical advice; dosing decisions for an approved drug belong with a prescribing clinician.
Overview
Tirzepatide’s evidence base comprises the SURPASS (diabetes), SURMOUNT (obesity), and cardiovascular/indication-specific programs (SUMMIT, SURPASS-CVOT, SURMOUNT-OSA), collectively tens of thousands of randomized participants in NEJM, The Lancet, and JAMA. Research clusters around the dual-incretin mechanism, glycemic control, weight reduction, cardiovascular and sleep-apnea outcomes, and safety. Evidence maturity is high, and multiple trials directly benchmark tirzepatide against semaglutide.
Dual GIP/GLP-1 Mechanism
The defining feature is simultaneous incretin-receptor agonism. The pivotal SURPASS-2 report by Frías et al. (2021) established tirzepatide as a dual GIP/GLP-1 agonist and defined the 5/10/15 mg once-weekly doses used across the program. Engaging GIP alongside GLP-1 is hypothesized to enhance insulin secretion and satiety additively, and network meta-analysis by Karagiannis et al. (2024) found subcutaneous tirzepatide outperformed subcutaneous semaglutide on glycemic and weight endpoints in type 2 diabetes.
Type 2 Diabetes (SURPASS)
The SURPASS trials established glycemic efficacy. In the head-to-head Frías et al. (2021) (SURPASS-2), tirzepatide produced greater reductions in HbA1c and body weight than semaglutide 1 mg in adults with type 2 diabetes — a landmark active-comparator result. Cardiovascular safety in diabetes with established atherosclerotic disease was subsequently assessed in Nicholls et al. (2025) (SURPASS-CVOT), a dedicated outcomes trial against dulaglutide.
Weight Management (SURMOUNT)
The SURMOUNT program extended tirzepatide to obesity. Jastreboff et al. (2022) (SURMOUNT-1) reported substantial, dose-dependent, sustained weight reduction over 72 weeks versus placebo in adults with obesity without diabetes. Garvey et al. (2023) (SURMOUNT-2) confirmed efficacy in people with both obesity and type 2 diabetes, and Aronne et al. (2024) (SURMOUNT-4) showed that continued treatment maintained weight loss while switching to placebo led to substantial regain. In the direct head-to-head Aronne et al. (2025) (SURMOUNT-5), tirzepatide achieved greater weight loss than semaglutide.
Cardiovascular, Sleep Apnea, and Long-Term Outcomes
Tirzepatide’s benefits extend beyond glycemia and weight. Packer et al. (2025) (SUMMIT) reported reduced cardiovascular death and worsening heart failure in HFpEF with obesity. Malhotra et al. (2024) (SURMOUNT-OSA) showed reduced apnea-hypopnea index in moderate-to-severe obstructive sleep apnea with obesity, supporting the OSA indication. Three-year data from Jastreboff et al. (2025) found tirzepatide delayed progression from prediabetes to type 2 diabetes with sustained weight loss.
Methodological Observations
The tirzepatide literature is built on large, well-powered RCTs with placebo and active comparators, multi-year follow-up, and hard endpoints — mirroring the rigor of the semaglutide program. Several trials use semaglutide or dulaglutide as active comparators, giving unusually direct evidence of relative efficacy. Synthesis-level evidence, such as the systematic review by Moiz et al. (2025), contextualizes tirzepatide within the broader incretin class.
Safety, GI Effects, and Limitations
- Gastrointestinal effects — Nausea, diarrhea, vomiting, and constipation are the most common adverse events and the main reason for dose reduction or discontinuation.
- Gastric emptying and drug interactions — Skelley et al. (2024) note pronounced delayed gastric emptying with implications for oral contraceptive absorption.
- Body composition — Meta-analysis by Karakasis et al. (2025) highlights fat-mass reduction alongside concerns about concurrent lean-mass loss across the incretin class.
- Boxed warning — A rodent thyroid C-cell tumor signal underlies a contraindication in personal/family history of medullary thyroid carcinoma or MEN 2.
- Compounded vs approved product — Research “reconstitution” tirzepatide is not the quality-controlled approved product; potency and purity of non-pharmacy sources are not assured.
Reconstitution Mathematics
Some tirzepatide is supplied as a lyophilized powder requiring reconstitution. The interactive calculator on this page handles all the arithmetic — but understanding the underlying formula is useful for verification:
Concentration (mg/mL) = Vial Size (mg) ÷ BAC Water Added (mL)
Dose Volume (mL) = Desired Dose (mg) ÷ Concentration (mg/mL)
Syringe Units (IU) = Dose Volume (mL) × 100 [for U-100 insulin syringe]Common reconstitution examples:
| Vial Size | BAC Water | Concentration | 2.5 mg dose |
|---|---|---|---|
| 10 mg | 2 mL | 5.0 mg/mL | 50 IU |
| 10 mg | 1 mL | 10 mg/mL | 25 IU |
| 20 mg | 2 mL | 10 mg/mL | 25 IU |
Use the interactive calculator on this page for any custom vial size, water volume, or dose.
Common Dosing Parameters
The following reflects the FDA-approved titration schedule for tirzepatide. Actual dosing must be directed by a prescribing clinician.
Approved tirzepatide dosing titrates gradually to limit gastrointestinal effects. IU values below assume a 10 mg vial reconstituted in 2 mL BAC water (5 mg/mL):
| Phase | Weekly Dose | Injection Volume | Syringe Units (IU) | Typical Duration |
|---|---|---|---|---|
| Initiation | 2.5 mg | 0.50 mL | 50 IU | Weeks 1–4 |
| Escalation | 5 mg | 1.00 mL | 100 IU | Weeks 5–8 |
| Escalation | 7.5 mg | 1.50 mL | 150 IU | Weeks 9–12 |
| Escalation | 10 mg | 2.00 mL | 200 IU | Weeks 13–16 |
| Maintenance | 15 mg | 3.00 mL | 300 IU | Ongoing (max) |
Key observations from the labeling and trials:
- The 2.5 mg starting dose is sub-therapeutic by design — it builds GI tolerance before efficacy doses
- Approved maintenance doses are 5, 10, or 15 mg weekly; escalation occurs in ≥4-week steps
- The SURPASS/SURMOUNT trials used the 5/10/15 mg dose ladder (Frías et al., 2021)
- Higher doses exceed 1 mL at 5 mg/mL — split injections or a higher concentration may be needed; verify against syringe capacity
Stability & Storage
| State | Temperature | Duration |
|---|---|---|
| Lyophilized (dry powder) | −20 °C (freezer) | 24+ months |
| Reconstituted in BAC water | 2–8 °C (refrigerator) | Up to 28 days |
| Reconstituted, room temp | 20–25 °C | 48 hours maximum |
Bacteriostatic water (BAC water, 0.9% benzyl alcohol) is the standard diluent for reconstitution because benzyl alcohol acts as a preservative. Approved single-dose pens and vials follow separate manufacturer storage instructions.
Reconstitution procedure (for lyophilized product):
- Allow vial to reach room temperature (~15 minutes)
- Wipe septum with 70% isopropyl alcohol
- Draw desired BAC water volume into a sterile syringe
- Insert needle at a 45° angle and inject slowly along the vial wall — do not inject directly onto the lyophilized cake
- Gently swirl (do not shake or vortex) until fully dissolved
- Label vial with date, concentration, and store per table above
Frequently Asked Questions
How many units do I draw for 2.5 mg of Tirzepatide?
It depends on your reconstitution ratio. With a 10 mg vial in 2 mL BAC water (5 mg/mL concentration), a 2.5 mg starting dose = 50 units on a U-100 insulin syringe. A 5 mg dose = 100 units. With 1 mL BAC water (10 mg/mL), 2.5 mg = 25 units. Use the calculator above for your specific setup.
What is the difference between Tirzepatide and Semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, while Semaglutide targets only the GLP-1 receptor. In head-to-head trials (SURPASS-2, SURMOUNT-5), tirzepatide produced greater HbA1c and weight reductions. Both are approved, effective, and dosed once weekly. Use the multi-peptide mode to model both.
Is Tirzepatide the same as Mounjaro and Zepbound?
Yes — tirzepatide is the active ingredient. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. Both deliver the same molecule via once-weekly injection.
How long does reconstituted Tirzepatide last in the refrigerator?
Reconstituted in bacteriostatic water and stored at 2–8 °C, tirzepatide is generally stable for up to 28 days. Approved pens and vials follow separate manufacturer dating. Always use a fresh alcohol swab before each draw, and discard cloudy or discolored solution.
Why does Tirzepatide dosing start at 2.5 mg?
The 2.5 mg initiation dose is designed to build tolerance to gastrointestinal side effects, not to treat — efficacy begins at the 5 mg dose and above. This stepwise titration in ≥4-week increments is a defining feature of the approved labeling and was used throughout the SURPASS and SURMOUNT trials.
FOR RESEARCH PURPOSES ONLY. Not for human consumption. Not for veterinary use. Not a drug, food, or cosmetic.